Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cfDNA-guided second-line treatment initiation in relapsed DLBCL/HGBCL
2024-518275-64-00Phase 2Authorised
- Sponsor
- Institute of Hematology and Transfusion Medicine
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab, polatuzumab vedotin, lisocabtagene maraleucel, axicabtagene ciloleucel, tafasitamab and 8 more in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma (3 arms), sponsored by Institute of Hematology and Transfusion Medicine. Primary endpoints: Overall response rate for cfDNA-guided second-line treatment and Grade 3-4 adverse reaction incidence. Planned start Dec 2024; status: authorised.
02
Drugs
glofitamabpolatuzumab vedotinlisocabtagene maraleucelaxicabtagene ciloleuceltafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on 2024-518275-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518275-64-00.